Shots:

• The US FDA has approved Lodoco for adult patients with atherosclerotic disease or with multiple risk factors for cardiovascular disease. Lodoco is expected to be available in H2’23
• The approval was based on the clinical trial evaluating Lodoco in 5522 patients with chronic coronary disease. The results showed that Lodoco (0.5mg) was found to significantly reduce the overall risk of CV death, spontaneous MI, ischemic stroke, or ischemia-driven coronary revascularization by 31% over PBO when added to high-intensity statins & other cardiology prevention therapies
• Lodoco, the first anti-inflammatory atheroprotective cardiovascular treatment that can be used alone or in combination with cholesterol-lowering medications

Ref: Businesswire | Image: Agepha Pharma

Related News:- Horizon Presents New P-IV Trial Results of Tepezza (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease at ENDO 2023

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com